Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) EBITDA: 2009-2025

Historic EBITDA for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $5.3 million.

  • Lifecore Biomedical's EBITDA rose 147.88% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 181.17%. This contributed to the annual value of -$17.2 million for FY2025, which is 94.99% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's EBITDA is $5.3 million, which was up 159.00% from -$9.0 million recorded in Q1 2025.
  • Lifecore Biomedical's 5-year EBITDA high stood at $15.6 million for Q1 2024, and its period low was -$36.5 million during Q1 2023.
  • Its 3-year average for EBITDA is -$3.9 million, with a median of -$4.3 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 13,302.74% in 2022, then skyrocketed by 213.56% in 2023.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's EBITDA stood at $3.7 million in 2021, then plummeted by 439.30% to -$12.5 million in 2022, then skyrocketed by 213.56% to $14.2 million in 2023, then slumped by 113.78% to -$2.0 million in 2024, then surged by 147.88% to $5.3 million in 2025.
  • Its EBITDA stands at $5.3 million for Q2 2025, versus -$9.0 million for Q1 2025 and -$2.0 million for Q4 2024.